亚临床与临床急性肾损伤具有相似的尿液肽段特征和预后
本研究为前瞻性、观察性、多国FROG-ICU队列研究的辅助分析,纳入1885例在入组时完成全部生物标志物测定的ICU患者,其中1154例无AKI(非AKI_KDIGO亚组,中位年龄60岁[48,71],321例(27.8%)死亡)。亚临床AKI(sAKI)定义为生物标志物(pNGAL、uNGAL、pCysC、uCysC、pPENKID、uLFABP)水平超过中位值而血肌酐不升高。无论采用哪种生物标志物定义,sAKI的尿液肽段特征均与临床AKI相似(炎症、溶血和内皮功能障碍),且这些特征与1年死亡率相关。结论认为生物标志物定义的sAKI在ICU中常见且严重,其尿液肽段特征与AKI相似,预后相当。
要点
- 在ICU患者中,以生物标志物(pNGAL、uNGAL、pCysC、uCysC、pPENKID、uLFABP)超过中位值定义的亚临床AKI(sAKI)与临床AKI(AKI_KDIGO)具有相似的尿液肽段特征。
- 非AKI_KDIGO亚组1154例患者中位年龄60岁[48,71],321例(27.8%)死亡。
- sAKI的尿液肽段特征涉及炎症、溶血和内皮功能障碍,且这些特征与1年死亡率相关。
- 生物标志物定义的sAKI在ICU中常见且严重,其预后与临床AKI相当,提示需关注无血肌酐升高的生物标志物阳性患者。
适用人群与场景
- ICU患者,为前瞻性、观察性、多国FROG-ICU队列研究的辅助分析人群。
- 纳入1885例在入组时完成全部生物标志物测定的患者,其中1154例无AKI(非AKI_KDIGO亚组),该亚组中位年龄60岁[48,71],321例(27.8%)死亡。
诊断标准与关键阈值
- AKI定义采用肾脏疾病改善全球预后(KDIGO)标准(AKI_KDIGO)。
- 亚临床AKI(sAKI)定义为生物标志物水平超过中位值而血肌酐不升高,生物标志物包括:中性粒细胞明胶酶相关脂质运载蛋白(pNGAL、uNGAL)、胱抑素C(pCysC、uCysC)、脑啡肽原A 119-159(pPENKID)和肝型脂肪酸结合蛋白(uLFABP)。
研究设计与关键结果
- 研究类型:前瞻性、观察性、多国FROG-ICU队列研究的辅助分析;样本量:1885例完成全部生物标志物测定的患者,其中非AKI_KDIGO亚组1154例。
- 非AKI_KDIGO亚组中位年龄60岁[48,71],321例(27.8%)死亡。
- 无论采用哪种生物标志物定义,sAKI的尿液肽段特征均与AKI_KDIGO相似(炎症、溶血和内皮功能障碍)。
- sAKI的尿液肽段特征与1年死亡率相关。
证据类型、等级与局限
- 证据类型:前瞻性、观察性、多国队列研究的辅助分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,生物标志物定义的亚临床AKI是ICU中常见且严重的状况,其尿液肽段特征与AKI相似,预后相当。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Acute kidney injury (AKI) is a frequent and severe condition in intensive care units (ICUs). In 2020, the Acute Dialysis Quality Initiative (ADQI) group proposed a new stage of AKI, referred to as stage 1S, which represents subclinical disease (sAKI) defined as a positive biomarker but no increase in serum creatinine (sCr). This study aimed to determine and compare the urinary peptide signature of sAKI as defined by biomarkers.
METHODS: This is an ancillary analysis of the prospective, observational, multinational FROG-ICU cohort study. AKI was defined according to the Kidney Disease Improving Global Outcome definition (AKIKDIGO). sAKI was defined based on the levels of the following biomarkers, which exceeded the median value: neutrophil gelatinase-associated lipocalin (pNGAL, uNGAL), cystatin C (pCysC, uCysC), proenkephalin A 119-159 (pPENKID) and liver fatty acid binding protein (uLFABP). Urinary peptidomics analysis was performed using capillary electrophoresis-mass spectrometry. Samples were collected at the time of study inclusion.
RESULTS: One thousand eight hundred eighty-five patients had all biomarkers measured at inclusion, which included 1154 patients without AKI (non-AKIKDIGO subgroup). The non-AKIKDIGO subgroup consisted of individuals at a median age of 60 years [48, 71], among whom 321 (27.8%) died. The urinary peptide signatures of sAKI, regardless of the biomarkers used for its definition, were similar to the urinary peptide signatures of AKIKDIGO (inflammation, haemolysis, and endothelial dysfunction). These signatures were also associated with 1-year mortality.
CONCLUSION: Biomarker-defined sAKI is a common and severe condition observed in patients within intensive care units with a urinary peptide signature that is similar to that of AKI, along with a comparable prognosis.
参考来源
- Boutin L, Latosinska A, Mischak H, et al. Subclinical and clinical acute kidney injury share similar urinary peptide signatures and prognosis. Intensive Care Med. 2023. PMID: 37670154. doi:10.1007/s00134-023-07198-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。